Related Experiment Videos
Newer insights into cisplatin nephrotoxicity
1Department of Medicine, New England Deaconess Hospital, Harvard Medical School, Boston, MA 02215.
The Annals of Pharmacotherapy
|December 1, 1993
Summary
Cisplatin is a crucial chemotherapy drug, but its use is limited by kidney damage (nephrotoxicity). Research is exploring protective agents to mitigate this side effect, improving cancer treatment safety.
Area of Science:
- Nephrology
- Oncology
- Pharmacology
Background:
- Cisplatin is a widely used chemotherapy agent for various solid tumors.
- Nephrotoxicity is a significant dose-limiting side effect of cisplatin therapy.
- Understanding cisplatin's mechanisms of kidney damage is crucial for patient management.
Purpose of the Study:
- To review recent advancements in understanding cisplatin-induced nephrotoxicity.
- To identify factors influencing cisplatin nephrotoxicity.
- To discuss potential protective agents against cisplatin nephrotoxicity.
Main Methods:
- Comprehensive literature search of MEDLINE and bibliographies.
- Inclusion of all relevant animal studies due to limited human data.
- Assessment of data on mechanisms, modifying factors, and management strategies.
Main Results:
- Cisplatin causes renal toxicity through proximal tubule damage, mitochondrial dysfunction, and altered calcium homeostasis.
- Factors like age, renal irradiation, and alcohol intake exacerbate cisplatin nephrotoxicity.
- Promising protective agents include NaCl/mannitol loading, sodium thiosulfate, WR 2721, glutathione, and probenecid.
Conclusions:
- Cisplatin is inherently nephrotoxic, posing a challenge in cancer therapy.
- Ongoing research is identifying agents to enhance the safety and efficacy of cisplatin treatment.
- Future therapeutic strategies aim to reduce cisplatin-induced kidney damage, improving patient outcomes.